A study analyzing susceptibility to 3Bnc117 and 10-1074 in Art-Suppressed Chronically Infected Persons
Latest Information Update: 25 Mar 2022
At a glance
- Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
Most Recent Events
- 25 Mar 2022 New trial record
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections